<DOC>
	<DOCNO>NCT00945451</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Stereotactic radiosurgery send x-ray directly tumor cause less damage normal tissue . Giving stereotactic radiosurgery docetaxel cisplatin may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose stereotactic radiosurgery give docetaxel , cisplatin , radiation therapy see well work treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Stereotactic Radiosurgery Treating Patients Undergoing Chemotherapy Radiation Therapy For Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate maximum tolerate dose stereotactic radiosurgery patient locally advance non-small cell lung cancer undergo concurrent chemoradiotherapy . ( Phase I ) - Assess response rate ( complete partial response ) patient RECIST criterion . ( Phase II ) Secondary - Determine tolerability . ( Phase I ) - Assess quality life patient QLQ-C30 v3 . ( Phase I ) - Assess overall disease-free survival patient . ( Phase II ) - Assess progression-free survival patient . ( Phase II ) OUTLINE : This multicenter , phase I dose escalation study stereotactic radiosurgery follow phase II study . Patients receive docetaxel IV cisplatin IV day 1 , 22 , 43 , 50 , 57 , 64 absence disease progression unacceptable toxicity . Beginning day 43 , patient undergo concurrent radiotherapy mediastinum 5 day week . Beginning 2-3 week chemoradiotherapy , patient undergo stereotactic radiosurgery day 1 , 3 , 5 . Quality life assess QLQ-C30 v3 questionnaire baseline , radiosurgery , 6 12 month completion study treatment . After completion study treatment , patient follow monthly 6 month , every 3 month 1 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer Locally advance disease No metastatic disease Unable undergo surgery concurrent chemoradiotherapy Must 13 tumor target mass &lt; 5 cm great diameter separate ≥ 2 cm concurrent chemoradiotherapy PATIENT CHARACTERISTICS : WHO performance status 02 Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 9 g/dL Neutrophil &gt; 1.0 x 10^9/L FEV_1 &gt; 30 % vital capacity Vital capacity &gt; 25 % predict value DLCO &gt; 25 % predict value LVEF ≥ 35 % PT &gt; 80 aPTT &gt; 35 sec Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment Not guardianship No dyspnea relate NYHA class IIIIV heart failure No indirect sign pulmonary arterial hypertension ( pulmonary arterial systolic BP &gt; 45 mm Hg ) No pulmonary acceleration time &lt; 100 m No contraindication fiducial insertion No geographical , social , psychological condition would interfere medical followup PRIOR CONCURRENT THERAPY : Docetaxel platinumbased drug concurrent irradiation allow No prior surgery surgery first phase treatment concurrent chemoradiotherapy No prior irradiation lung No concurrent participation another study trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
</DOC>